🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

311 results for “International” Clear

  1. JNJ-73841937, JNJ-61186372

    Janssen-Cilag International N.V.

    Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. JNJ-73841937, Montelukast Sodium Tablets, Dexamethason 4 mg JENAPHARM®, Methotrexat-Ebewe, 10mg/ml, roztwór do wstrzykiwań, JNJ-61186372, Methotrexate

    Janssen-Cilag International N.V.

    EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. JNJ-73841937, PEMETREXED , JNJ-61186372, CARBOPLATIN

    Janssen-Cilag International N.V.

    Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer.

    phase 2 small molecule active

    1 trial

  4. JNJ-77242113

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 2 small molecule completed

    1 trial

  5. JNJ-79635322, JNJ-79635322

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 2 small molecule active

    1 trial

  6. JNJ-80202135, JNJ-80202135, Saline, 0.9% Sodium Chloride Solution for Injection

    Janssen-Cilag International N.V.

    Active Idiopathic Inflammatory Myopathies (IIM)

    phase 2 small molecule active

    1 trial

  7. JNJ-81241459, JNJ-81241459 200mg, placebo tablet, JNJ-81241459, JNJ-81241459 50mg, placebo tablet

    Janssen-Cilag International N.V.

    Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  8. JNJ-88545223, JNJ-88545223, JNJ-88545223 Placebo

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 2 small molecule active

    1 trial

  9. JNJ-95475939, Placebo JNJ-95475939, Dupixent 300 mg solution for injection in pre-filled syringe

    Janssen-Cilag International N.V.

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  10. KPL-387

    Kiniksa Pharmaceuticals International, plc

    Well-Controlled Recurrent Pericarditis

    phase 2 small molecule active

    1 trial

  11. KPL-387

    Kiniksa Pharmaceuticals International, plc

    Recurrent Pericarditis

    phase 2 small molecule active

    1 trial

  12. KPL-404

    Kiniksa Pharmaceuticals International, plc

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  13. KPL-716

    Kiniksa Pharmaceuticals International, plc

    Chronic Idiopathic Urticaria

    phase 2 small molecule completed

    1 trial

  14. KPL-914

    Kiniksa Pharmaceuticals International, plc

    Recurrent Pericarditis

    phase 2 small molecule completed

    1 trial

  15. Kenacort-A 40, suspensie voor injectie 40 mg/ml, JNJ-81201887, Placebo to match Prednisone 20mg, 5mg, JNJ-81201887, Prednison acis 20 mg, Tabletten, Prednison acis 5 mg, Tabletten

    Janssen-Cilag International N.V.

    Geographic Atrophy

    phase 2 small molecule active

    1 trial

  16. LUM001

    Mirum Pharmaceuticals International B.V.

    Alagille Syndrome

    phase 2 small molecule completed

    2 trials

  17. LUM001

    Mirum Pharmaceuticals International B.V.

    Primary Biliary Cirrhosis

    phase 2 small molecule terminated

    1 trial

  18. LUM001

    Mirum Pharmaceuticals International B.V.

    Primary Sclerosing Cholangitis (PSC)

    phase 2 small molecule completed

    1 trial

  19. LUM001

    Mirum Pharmaceuticals International B.V.

    PBC

    phase 2 small molecule completed

    1 trial

  20. LUM001 (Maralixibat)

    Mirum Pharmaceuticals International B.V.

    Alagille Syndrome

    phase 2 small molecule completed

    3 trials

  21. LUM001 (Maralixibat)

    Mirum Pharmaceuticals International B.V.

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    phase 2 small molecule completed

    1 trial

  22. Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 20 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, Lenalidomide Accord 2.5 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, IMBRUVICA 140 mg hard capsules, Lenalidomide Accord 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Accord 15 mg hard capsules, Lenalidomide Accord 15 mg hard capsules, JNJ-54179060, Lenalidomide Accord 2.5 mg hard capsules, Ruxi

    Janssen-Cilag International N.V.

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  23. Low dose of MRM-3379

    Mirum Pharmaceuticals International B.V.

    Fragile X Syndrome

    phase 2 small molecule active

    1 trial

  24. Lumicitabine

    Janssen Cilag International NV

    Respiratory Syncytial Viruses

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources